pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

maia-biotechnology PRESS RELEASE ARCHIVE

Sep 29, 2022

MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 8, 2022

MAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022

MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022

Aug 30, 2022

MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids

Aug 22, 2022

MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 2, 2022

MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)

Aug 1, 2022

MAIA Biotechnology Announces Closing of Initial Public Offering

Jul 27, 2022

MAIA Biotechnology Announces Pricing of Initial Public Offering

Jul 18, 2022

MAIA Biotechnology Doses First Patient With THIO in Phase 2 Trial (THIO-101) for Non-Small Cell Lung Cancer

Jun 14, 2022

MAIA Biotechnology, Inc. Announces Research Collaboration with Nationwide Children’s Hospital to Evaluate THIO in Combination with Standard-of-Care Cancer Therapies

May 19, 2022

MAIA Biotechnology, Inc. Establishes Wholly Owned Subsidiaries in Romania and Australia to Support Global Development of THIO

Apr 26, 2022

MAIA Biotechnology, Inc. Announces FDA Orphan Drug Designation for THIO for the Treatment of Hepatocellular Carcinoma (HCC)

Mar 16, 2022

MAIA Biotechnology, Inc. Announces $2.4 Million Financing to Advance Targeted Immuno-Oncology Studies

Mar 15, 2022

MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC

Nov 9, 2021

MAIA Biotechnology, Inc. Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)

Oct 14, 2021

MAIA Biotechnology, Inc. Announces $6.2 Million Financing to Advance Targeted Immuno-Oncology Studies

Sep 28, 2021

MAIA Biotechnology, Inc. Announces the Appointment of Steven M. Chaouki to Its Board of Directors

Sep 15, 2021

MAIA Biotechnology, Inc. Announces Formation of Scientific Advisory Board

Aug 17, 2021

MAIA Biotechnology, Inc. Appoints Joseph F. McGuire as Chief Financial Officer and Provides Corporate Update

Aug 4, 2021

MAIA Biotechnology, Inc. Announces Additions to Executive Team and Board of Directors

May 19, 2021

MAIA Biotechnology, Inc. Raises $8.0 Million Financing to Advance Pipeline of Targeted Immuno-Oncology Studies

Mar 25, 2021

MAIA Biotechnology to Present at Upcoming Investor Conferences

Feb 2, 2021

MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo (cemiplimab) in Advanced Non-Small Cell Lung Cancer

Jul 7, 2020

MAIA Biotechnology, Inc. Announces Publication in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO

Google Analytics Alternative